David C. Blakey

5.1k citations

52 papers · 3.6k indexed · 1 hit paper · h-index 25

Impact in

Biomaterials top 1%
- Nanoparticle-Based Drug Delivery
Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism

Papers in

Cancer Research 13
- Cancer, Hypoxia, and Metabolism 8
- MicroRNA in disease regulation 3
Biotechnology 7
- Transgenic Plants and Applications 6

Co-authors: Simon T. Barry Alberto Gabizón Hiroshi Maeda Omid C. Farokhzad William C. Zamboni Eva M. Sevick‐Muraca Rakesh K. Jain Piotr Grodzinski
Journals: Cancer Research (3 papers)Molecular Cancer Therapeutics (3 papers)Molecular Therapy (3 papers)Neoplasia (2 papers)Clinical Cancer Research (2 papers)
Partner nations: United Kingdom United States Taiwan

In The Last Decade

David C. Blakey

50 papers receiving 3.4k citations

Hit Papers

align trajectories log scale

Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology 2013 · 1.2k citations

Peers

Countries citing papers authored by David C. Blakey

Since Specialization

Citations

This map shows the geographic impact of David C. Blakey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David C. Blakey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David C. Blakey more than expected).

Fields of papers citing papers by David C. Blakey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David C. Blakey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David C. Blakey. The network helps show where David C. Blakey may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David C. Blakey, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David C. Blakey Line = papers co-authored together David C. Blakey links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Enhancing SIRT1 Gene Expression Using Small Activating RNAs: A Novel Approach for Reversing Metabolic Syndrome Nucleic Acid Therapeutics ·Pinelopi Andrikakou, Vikash Reebye, Daniel Vasconcelos, Sorah Yoon, Jon Voutila, Andrew J.T. George, Piotr Swiderski, Robert Habib, Matthew C. Catley, David C. Blakey, Nagy Habib, John J. Rossi, Kai‐Wen Huang	2022	11
2	Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug Molecular Therapy ·Alexandre J. Debacker, Jon Voutila, Matthew C. Catley, David C. Blakey, Nagy Habib	2020	235
3	Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer Oncogene ·Vikash Reebye, Kai‐Wen Huang, Vivian Lin, Sheba Jarvis, Rattanachart Sirinil, Stephanie Dorman, حسام حرجان عجاج العيساوي, Pinelopi Andrikakou, Jon Voutila, Pål Sætrom, Paul J. Mintz, Isabella Reccia, John J. Rossi, Hans E. Huber, Robert Habib, Ruth Beale, David C. Blakey, Nagy Habib	2018	73
4	Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS Science Translational Medicine ·Sarah J. Ross, Alexey S. Revenko, Lyndsey Hanson, Rebecca Ellston, Anna D. Staniszewska, Nicky Whalley, Sanjay K. Pandey, Mitchell Revill, Claire Rooney, Linda K. Buckett, Stéphanie Klein, Kevin Hudson, Brett P. Monia, Michael Zinda, David C. Blakey, Paul D. Lyne, A. Robert MacLeod	2017	143
5	Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer Molecular Therapy ·Jon Voutila, Vikash Reebye, Thomas C. Roberts, Nolan Swain, Pinelopi Andrikakou, David C. Blakey, Robert Habib, Hans E. Huber, Pål Sætrom, John J. Rossi, Nagy Habib	2017	85
6	Inhibition of Platelet-Derived Growth Factor Receptor α by MEDI-575 Reduces Tumor Growth and Stromal Fibroblast Content in a Model of Non-Small Cell Lung Cancer Molecular Pharmacology ·Naomi Laing, Songyuan Luo, Shenghua Wen, David C.H. Yang, Ольга Шпилєва, Michael P. Collins, Corinne Reimer, Peter A. Hall, Harriet Andersén, Michael Snaith, Xin Wang, Vahe Bedian, Zhu Cao, David C. Blakey	2013	14
7	MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo Molecular Cancer Therapeutics ·David W. Jenkins, Sarah J. Ross, Margaret H. Veldman-Jones, Ian N. Foltz, Linjiong Zhu, Kathy Manchulenko, Cath Eberlein, Jane Kendrew, Philip Petteruti, Song Cho, Melissa Damschroder, Li Peng, Dawn Baker, Neil R. Smith, Hazel M. Weir, David C. Blakey, Vahe Bedian, Simon T. Barry	2012	47
8	Dual IGF-I/II–Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth Cancer Research ·Frederick Hadleigh West, Jon Chesebrough, Richard Bonson, Sally‐Ann Ricketts, Rhoda Kumah, Margaret H. Veldman-Jones, David C. Blakey, Mohammad Tabrizi, Bahija Jallal, Pamela A. Trail, Steven Coats, Klaus Bosslet, Yong S. Chang	2011	105
9	Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2‐specific antagonist is associated with reduced tumor growth International Journal of Cancer ·Simon Tazzyman, Simon T. Barry, Susan Ashton, Pauline J. Wood, David C. Blakey, Claire E. Lewis, Craig Murdoch	2011	89
10	A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models Molecular Cancer Therapeutics ·Jeffrey L. Brown, Zhe Cao, Maria Pinzon-Ortiz, Jane Kendrew, Corinne Reimer, Shenghua Wen, F Schönfeld, Mohammad Tabrizi, Robert W. Harbeson, Songyuan Luo, Lourdes Pablo, Patricia McCoon, Vahe Bedian, David C. Blakey	2010	113
11	Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies Investigational New Drugs ·Gadi Gazit Bornstein, Christophe Quéva, Mohammad Tabrizi, Anne van Abbema, Carlos M. Chavez, Ping Wang, Orit Foord, Joseppa Piñol, Naomi Laing, Rubing Mo, Shenghua Wen, Larry L. Green, Xiaodong Yang, Carl I. Webster, Ross Stewart, David C. Blakey	2009	20
12	Acute Tumor Response to ZD6126 Assessed by Intrinsic Susceptibility Magnetic Resonance Imaging Neoplasia ·Simon P. Robinson, Tammy L. Kalber, Franklyn A. Howe, Dominick J. O. McIntyre, John R. Griffiths, David C. Blakey, Prabhakar Thirumal Appaswamy, Anderson J. Ryan, John C. Waterton	2005	28
13	Single Dose of the Antivascular Agent, ZD6126 (N-Acetylcoichinol-O-Phosphate), Reduces Perfusion for at Least 96 Hours in the GH3 Prolactinoma Rat Tumor Model Neoplasia ·Dominick J. O. McIntyre, Simon P. Robinson, Franklyn A. Howe, John R. Griffiths, Anderson J. Ryan, David C. Blakey, Ian Peers, John C. Waterton	2004	29
14	ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Oxford University Research Archive (ORA) (University of Oxford) ·Peter D. Davis, Graeme J. Dougherty, David C. Blakey, Susan Galbraith, Gillian M. Tozer, Angela Holder, Matthew A. Naylor, John Nolan, Michael R.L. Stratford, David J. Chaplin, Sally A. Hill	2002	200
15	Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. PubMed ·Hisatsugu Goto, Seiji Yano, Helong Zhang, HUANG Jialing, Hirohisa Ogawa, David C. Blakey, Saburo Sone	2002	72
16	DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767 European Journal of Cancer ·Noel R. Monks, David C. Blakey, Lily C. Johnston, Robert I. Dowell, A. Mahadeven-Jensen, Nicola J. Curtin, Christine E. Arris, David R. Newell	2002	21
17	ZD6126: A novel small molecule vascular targeting agent International Journal of Radiation OncologyBiologyPhysics ·David C. Blakey, Susan Ashton, F. Russell Westwood, Mike Walker, Anderson J. Ryan	2002	52
18	Simulated bone metastases: A case study of two patients with breast cancer Australasian Radiology ·Jill Ainslie, Rodney J. Hicks, Putri Wulandini S, David C. Blakey, Sarah Landis	1999	2
19	Radiotherapy treatment for isolated loco-regional recurrence of rectosigmoid cancer following definitive surgery: Peter maccallum cancer institute experience, 1981–1990 International Journal of Radiation OncologyBiologyPhysics ·Michael Guiney, Jennifer Smith, M. Schirtzinger, Sam Ngan, David C. Blakey	1997	17
20	Postoperative radiotherapy for DukesB ‘ and C rectal cancer: Peter MacCallum Cancer Institute experience Australasian Radiology ·Michael Guiney, Jennifer Smith, M. Schirtzinger, Sam Ngan, David C. Blakey	1996	0

About David C. Blakey

David C. Blakey is a scholar working on Cancer Research, Biotechnology, Oncology, Radiology, Nuclear Medicine and Imaging and Immunology, having authored 52 papers that have together received 3.6k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (11 papers), Angiogenesis and VEGF in Cancer (10 papers), Cancer, Hypoxia, and Metabolism (8 papers), Toxin Mechanisms and Immunotoxins (7 papers), Transgenic Plants and Applications (6 papers), HER2/EGFR in Cancer Research (4 papers), Glycosylation and Glycoproteins Research (3 papers) and MicroRNA in disease regulation (3 papers). The work is most often cited by research in Biomaterials (773 citations), Cancer Research (593 citations), Biotechnology (289 citations), Molecular Biology (1.9k citations) and Immunology (531 citations). David C. Blakey has collaborated with scholars based in United Kingdom, United States and Taiwan. Frequent co-authors include Simon T. Barry, Alberto Gabizón, Hiroshi Maeda, Omid C. Farokhzad, William C. Zamboni, Eva M. Sevick‐Muraca, Rakesh K. Jain, Piotr Grodzinski, Uma Prabhakar and Philip E. Thorpe. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Molecular Therapy, Neoplasia and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact